The human aldo-keto reductase (AKR) 1C3, also known as
type-5 17β-hydroxysteroid dehydrogenase and prostaglandin F
synthase, has been suggested as a therapeutic target in the treatment
of prostate and breast cancers. In this study, AKR1C3 inhibition was
examined by Brazilian propolis-derived cinnamic acid derivatives that
show potential antitumor activity, and it was found that baccharin
(1) is a potent competitive inhibitor (Ki 56 nM) with high selectivity, showing no significant
inhibition toward other AKR1C isoforms (AKR1C1, AKR1C2, and AKR1C4).
Molecular docking and site-directed mutagenesis studies suggested
that the nonconserved residues Ser118, Met120, and Phe311 in AKR1C3
are important for determining the inhibitory potency and selectivity
of 1. The AKR1C3-mediated metabolism of 17-ketosteroid
and farnesal in cancer cells was inhibited by 1, which
was effective from 0.2 μM with an IC50 value of about
30 μM. Additionally, 1 suppressed the proliferation
of PC3 prostatic cancer cells stimulated by AKR1C3 overexpression.
This study is the first demonstration that 1 is a highly
selective inhibitor of AKR1C3.